Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279422 · ClinicalTrials.gov registry record · Phase 2
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
A Phase 2 study, sponsored by Facet Biotech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT00279422 is a Phase 2 study that was terminated before completion, run by Facet Biotech. The registered enrollment target is 127 participants.
The verdict
NCT00279422, a Phase 2 study, was terminated before completion, sponsored by Facet Biotech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
Interventions
- DRUG visilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279422
The ClinicalTrials.gov registry entry for NCT00279422 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Facet Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which visilizumab is the first listed.
NCT00279422 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00279422 about?
NCT00279422 is a clinical study titled "A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis". The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
What is the current status of trial NCT00279422?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2006-02. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00279422?
The interventions under investigation include: visilizumab (DRUG).
Who is sponsoring clinical trial NCT00279422?
This trial is sponsored by Facet Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.